期刊
VACCINES
卷 9, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9090969
关键词
therapeutic vaccination; hepatitis B surface antigen (HBsAg); hepatitis B virus (HBV) specific T-cells; HBV functional cure; non-human primate; electroporation
资金
- Janssen
Despite the availability of a prophylactic vaccine for HBV for over 30 years, nearly 300 million people are still chronically infected worldwide. Chronic HBV patients exhibit weak CD8(+) T-cell responses, but a therapeutic DNA vaccine has shown to induce robust immune responses in both healthy and infected animal models.
Despite the availability of an effective prophylactic vaccine for more than 30 years, nearly 300 million people worldwide are chronically infected with the hepatitis B virus (HBV), leading to 1 death every 30 s mainly from viral hepatitis-related cirrhosis and liver cancer. Chronic HBV patients exhibit weak, transient, or dysfunctional CD8(+) T-cell responses to HBV, which contrasts with high CD8+ T-cell responses seen for resolvers of acute HBV infection. Therefore, a therapeutic DNA vaccine was designed, expressing both HBV core and polymerase proteins, and was sequence optimized to ensure high protein expression and secretion. Although the vaccine, administered intramuscularly via electroporation, had no effect on plasma viral parameters in a mouse model of persistent HBV infection, it did induce robust HBV-specific immune responses in healthy and adeno-associated hepatitis B virus (AAV-HBV) infected mice as well as in healthy non-human primates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据